OXPHOS-IN-3 是一种线粒体靶向的双重 OXPHOS/glycolysis 抑制剂,对胰腺癌细胞具有显著的抗增殖活性,可诱导线粒体功能障碍、铁死亡 (ferroptosis) 和免疫原性细胞死亡 (ICD),并在胰腺导管腺癌 (PDAC) 模型中表现出显著的抗肿瘤活性。
OXPHOS-IN-3
产品编号: MS-A10054 分子式: C49H55BrClF3N3O5PS 分子量: 1001.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

OXPHOS-IN-3 是一种线粒体靶向的双重 OXPHOS/glycolysis 抑制剂,对胰腺癌细胞具有显著的抗增殖活性,可诱导线粒体功能障碍、铁死亡 (ferroptosis) 和免疫原性细胞死亡 (ICD),并在胰腺导管腺癌 (PDAC) 模型中表现出显著的抗肿瘤活性。

生物实验数据

生物活性 OXPHOS-IN-3 is a mitochondria-targeted dual OXPHOS/glycolysis inhibitor that exhibits potent antiproliferative activity against pancreatic cancer cells, induces mitochondrial dysfunction, ferroptosis, and immunogenic cell death (ICD), and demonstrates significant antitumor activity in pancreatic ductal adenocarcinoma (PDAC) models.
IC50 & Target

SIRT3

 

GPX4

 

体外研究
(In Vitro)

OXPHOS-IN-3 (Compound 14c) (0.1-0.8 μM; 24-72 小时) 在缺氧 MIAPaCa-2 细胞中显示出强效抗增殖活性 (IC50 = 0.27 μM),对正常 HS-5 和 L02 细胞具有良好选择性 (IC50 > 20 μM)。
OXPHOS-IN-3 (0.1-0.8 μM; 24-72 小时) 剂量依赖性抑制缺氧 MIAPaCa-2 细胞的克隆形成、迁移和侵袭,并下调上皮-间质转化 (EMT) 标志物。
OXPHOS-IN-3 (0.1-2.0 μM; 12-72 小时) 抑制 PDKs (IC50 = 97.8 nM),降低 PDH 磷酸化 (EC50 = 14.3 nM),减少乳酸产生,并抑制缺氧条件下的糖酵解参数。
OXPHOS-IN-3 (0.2-2.0 μM; 12-48 小时) 下调 SDHB 和 SIRT3,诱导线粒体功能障碍并触发铁死亡,在缺氧 MIAPaCa-2 细胞中凋亡水平较低。
OXPHOS-IN-3 (0.2-2.0 μM; 12-48 小时) 在胰腺癌细胞系 MIAPaCa-2中诱导线粒体 ROS 积累、MMP 塌陷、mPTP 开放及细胞色素 c 释放。
OXPHOS-IN-3 (0.2-2.0 μM; 12-24 小时) 诱导人胰腺癌细胞 MIAPaCa-2发生免疫原性细胞死亡特征,包括 CRT 表面暴露、HMGB1 转位/释放及细胞内 ATP 耗竭。

Cell Viability Assay

Cell Line: MIAPaCa-2, PANC-1, BxPC-3 (normoxic and hypoxic), HS-5, L02 cells
Concentration: 0.1, 0.4, 0.8 μM (and broader range for IC50 determination)
Incubation Time: 24-72 h
Result: Inhibited cell viability in PDAC cells, showing IC50 values of 0.27 μM, 6.25 μM, and 3.15 μM against MIAPaCa-2, PANC-1, and BxPC-3 cells under hypoxic conditions, respectively.
Exhibited IC50 values of 3.36 μM, 2.07 μM, and 2.06 μM against MIAPaCa-2, PANC-1, and BxPC-3 cells under normoxic conditions, respectively.
Showed markedly reduced cytotoxicity to normal HS-5 and L02 cells (IC50 > 20 μM).

Cell Proliferation Assay

Cell Line: MIAPaCa-2 cells (hypoxic)
Concentration: 0.1, 0.4, 0.8 μM
Incubation Time: 72 h (followed by 10-14 days culture)
Result: Dose-dependently suppressed clonogenic capacity, while Gemcitabine (MS-T87535) showed weakened effect under hypoxia.

Cell Migration Assay

Cell Line: MIAPaCa-2 cells (hypoxic)
Concentration: 0.1, 0.4, 0.8 μM
Incubation Time: 24 h
Result: Significantly inhibited wound healing and transwell migration.

Cell Invasion Assay

Cell Line: MIAPaCa-2 cells (hypoxic, Matrigel-coated)
Concentration: 0.1, 0.4, 0.8 μM
Incubation Time: 48 h
Result: Effectively inhibited the invasive potential of MIAPaCa-2 cells under hypoxic conditions

Western Blot Analysis

Cell Line: MIAPaCa-2 (hypoxic), PANC-1, BxPC-3 cells
Concentration: 0.2, 1.0, 2.0 μM
Incubation Time: 12-72 h
Result: Reduced expression of p-PDH, SDHB, SIRT3, EMT markers (ZEB1, Slug, Vimentin, Snail, N-cadherin), xCT and GPX4.
Increased HIF-1α and PDK1 expression under hypoxic validation.

Immunofluorescence

Cell Line: MIAPaCa-2 cells (hypoxic)
Concentration: 0.2, 1.0, 2.0 μM
Incubation Time: 12-24 h
Result: Promoted CRT surface exposure and HMGB1 nuclear-to-cytoplasmic translocation, visualized by confocal microscopy.

Apoptosis Analysis

Cell Line: MIAPaCa-2 cells (hypoxic)
Concentration: 0.2, 1.0, 2.0 μM
Incubation Time: 24-48 h
Result: Induced only low-level apoptosis (≤15%), which was not the primary mode of cell death.
体内研究
(In Vivo)

OXPHOS-IN-3 (Compound 14c) (5 mg/kg;瘤内注射;每 2 天一次,共 3 剂) 在 C57BL/6 小鼠同基因双侧 PANC02 模型中显著抑制原发肿瘤和远端未治疗肿瘤的生长,显示全身抗肿瘤免疫活性。
OXPHOS-IN-3 (5 和 10 mg/kg;腹腔注射;每 2 天一次,共 6 剂) 在 C57BL/6 小鼠同基因 PANC02-EGFP 皮下移植瘤模型中剂量依赖性抑制肿瘤生长,同时下调肿瘤组织中 p-PDH、SDHB、SIRT3 和 EMT 标志物。。

Animal Model: Syngeneic bilateral PANC02 model (Male C57BL/6 mice, 6-8 weeks old)
Dosage: 5 mg/kg
Administration: Intratumoral injection (i.t.), every 2 days for 3 doses
Result: Reduced primary and contralateral tumor volume/weight compared with control and Gemcitabine (MS-T87535) groups.
Decreased Arg-1 and MRC-1 expression in tumor tissues (M1-like TAM reprogramming).
Enhanced HMGB1 release and CRT exposure in tumor sections (IHC/IF).
No significant body weight loss.
Animal Model: Syngeneic PANC02-EGFP subcutaneous model (Male C57BL/6 mice, 6-8 weeks old)
Dosage: 5 and 10 mg/kg
Administration: Intraperitoneal injection (i.p.), every 2 days for 6 doses
Result: Dose-dependently inhibited tumor growth as shown by reduced EGFP fluorescence, caliper measurement, and tumor weight.
Decreased p-PDH, SDHB, SIRT3, and EMT markers in tumor tissues.
Showed pronounced tumor cell damage with normal histology in major organs (heart, liver, spleen, lung, kidney).
Exhibited good tolerability with stable body weight throughout the treatment period.

化学信息

分子量 1001.37
分子式 C49H55BrClF3N3O5PS

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础